Equity indices flat amid lacklustre trading, HUL dips 1 pc

ANI
04 May 2021, 15:18 GMT+10

Mumbai (Maharashtra) [India], May 4 (ANI): Key equity indices were range-bound during early hours on Tuesday as the fear of a continuous rise in Covid cases and extended lockdowns in various states capped market sentiment.

At 10:15 am, the BSE SP Sensex was up by 34 points or 0.08 per cent at 48,752 while the Nifty 50 ticked up by 12 points or 0.08 per cent to 14,646.

Sectoral indices at the National Stock Exchange were mixed with Nifty PSU bank gaining by 2.3 per cent but financial service, FMCG and pharma were in the red.

Among stocks, FMCG major Hindustan Unilever dropped by 1 per cent to Rs 2,382.30 per share and Reliance Industries slipped by 1.2 per cent.

The other major losers were Wipro, HDFC Bank, Titan, Maruti Suzuki and Tata Consumer Products. However, those with marginal gains included Hindalco, ONGC, State Bank of India, Axis Bank and ICICI Bank.

Meanwhile, Asia's share markets were mostly higher as regional equity investors looked to signs of recovery from the coronavirus pandemic while major economies around the world reopen.

MSCI's broadest index of Asia Pacific shares outside Japan was up by 0.05 per cent on the back of a positive lead from Wall Street overnight.

Hong Kong's Hang Seng Index opened 0.3 per cent higher. Japan and mainland China's markets remained closed for holidays, dampening trading volumes across the region. (ANI)

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Japan Herald.

More Information

24 ℃

null in Tokyo

Asia Pacific

Section

China should target Australian military sites, says newspaper editor

China should consider "long-range strikes" if war with the West eventuates, according to an editorial in the country's pro-government newspaper ...

WHO says "low confidence" in Sinopharm Covid side-effects data

GENEVA, Switzerland: World Health Organization experts have said they have "very low confidence" in data received from Chinese state-owned drugmaker ...